FDA Determines Regulatory Review Period for ARGUS II VISUAL STIMULATION SYSTEM Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of the ARGUS II VISUAL STIMULATION SYSTEM, a medical device, following a submission to the U.S. Patent and Trademark Office (USPTO). This determination is required by law and has been published as a notice.